ORASURE TECHNOLOGIES INC (OSUR) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ORASURE TECHNOLOGIES INC Do?
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania. ORASURE TECHNOLOGIES INC (OSUR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Carrie E. Manner and employs approximately 840 people, headquartered in BETHLEHEM, Pennsylvania. With a market capitalization of $207M, OSUR is one of the notable companies in the Healthcare sector.
ORASURE TECHNOLOGIES INC (OSUR) Stock Rating — Reduce (April 2026)
As of April 2026, ORASURE TECHNOLOGIES INC receives a Reduce rating with a composite score of 31.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OSUR ranks #2,373 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ORASURE TECHNOLOGIES INC ranks #258 of 839 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
OSUR Stock Price and 52-Week Range
ORASURE TECHNOLOGIES INC (OSUR) currently trades at $3.08. The 52-week high for OSUR is $4.22, which means the stock is currently trading -27.0% from its annual peak. The 52-week low is $2.08, putting the stock 48.1% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is OSUR Overvalued or Undervalued? — Valuation Analysis
ORASURE TECHNOLOGIES INC (OSUR) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.62x, versus the sector average of 2.69x. The price-to-sales ratio is 1.64x, compared to 1.64x for the average Healthcare stock.
At current multiples, ORASURE TECHNOLOGIES INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
ORASURE TECHNOLOGIES INC Profitability — ROE, Margins, and Quality Score
ORASURE TECHNOLOGIES INC (OSUR) earns a quality factor score of 35/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -15.8%, compared to the Healthcare sector average of -42.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -13.4% versus the sector average of -33.1%.
On a margin basis, ORASURE TECHNOLOGIES INC reports gross margins of 42.4%, compared to 71.3% for the sector. The operating margin is -47.9% (sector: -65.2%). Net profit margin stands at -44.6%, versus -54.1% for the average Healthcare stock. Revenue growth is running at -50.1% on a trailing basis, compared to 10.7% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
OSUR Debt, Balance Sheet, and Financial Health
ORASURE TECHNOLOGIES INC has a debt-to-equity ratio of 18.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.58x, indicating strong short-term liquidity. Total debt on the balance sheet is $17M. Cash and equivalents stand at $216M.
OSUR has a beta of 1.14, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ORASURE TECHNOLOGIES INC is 45/100, reflecting average volatility within the normal range for its sector.
ORASURE TECHNOLOGIES INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, ORASURE TECHNOLOGIES INC reported revenue of $128M and earnings per share (EPS) of $-0.94. Net income for the quarter was $-54M. Gross margin was 42.4%. Operating income came in at $-58M.
In FY 2025, ORASURE TECHNOLOGIES INC reported revenue of $115M and earnings per share (EPS) of $-0.94. Net income for the quarter was $-69M. Gross margin was 41.9%. Revenue grew -38.1% year-over-year compared to FY 2024. Operating income came in at $-72M.
In Q3 2025, ORASURE TECHNOLOGIES INC reported revenue of $27M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-14M. Gross margin was 43.5%. Revenue grew -32.1% year-over-year compared to Q3 2024. Operating income came in at $-16M.
In Q2 2025, ORASURE TECHNOLOGIES INC reported revenue of $31M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-20M. Gross margin was 42.1%. Revenue grew -42.5% year-over-year compared to Q2 2024. Operating income came in at $-18M.
Over the past 8 quarters, ORASURE TECHNOLOGIES INC has demonstrated a growth trajectory, with revenue expanding from $54M to $128M. Investors analyzing OSUR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
OSUR Dividend Yield and Income Analysis
ORASURE TECHNOLOGIES INC (OSUR) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
OSUR Momentum and Technical Analysis Profile
ORASURE TECHNOLOGIES INC (OSUR) has a momentum factor score of 38/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
OSUR vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ORASURE TECHNOLOGIES INC (OSUR) ranks #258 out of 839 stocks based on the Blank Capital composite score. This places OSUR in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.5/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.3/100, HOLOGIC INC (HOLX) with a score of 52.8/100, FONAR CORP (FONR) with a score of 53.0/100, and Royalty Pharma plc (RPRX) with a score of 53.4/100.
Comparing OSUR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OSUR vs S&P 500 (SPY) comparison to assess how ORASURE TECHNOLOGIES INC stacks up against the broader market across all factor dimensions.
OSUR Next Earnings Date
No upcoming earnings date has been announced for ORASURE TECHNOLOGIES INC (OSUR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy OSUR? — Investment Thesis Summary
The quantitative profile for ORASURE TECHNOLOGIES INC suggests caution. The quality score of 35/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 38/100, a headwind for near-term performance.
In summary, ORASURE TECHNOLOGIES INC (OSUR) earns a Reduce rating with a composite score of 31.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OSUR stock.
Related Resources for OSUR Investors
Explore more research and tools: OSUR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OSUR head-to-head with peers: OSUR vs AZN, OSUR vs SLGL, OSUR vs HOLX.